What are the recommended treatment options for colitis based on its underlying cause (infectious, inflammatory, ischemic, or microscopic)?

Treatment of Colitis

Treatment of colitis must be tailored to the specific underlying etiology, as management differs fundamentally between microscopic, infectious, ischemic, and inflammatory bowel disease-related colitis.

Microscopic Colitis (Collagenous and Lymphocytic Colitis)

First-Line Induction Therapy

Budesonide 9 mg once daily for 6–8 weeks is the definitive first-line treatment for symptomatic microscopic colitis, achieving clinical remission in more than twice as many patients compared to no treatment (RR 2.52; 95% CI 1.45–4.4). 1, 2

• Clinical improvement typically begins within 7–13 days of initiating budesonide therapy 1, 2
• Budesonide demonstrates superior efficacy compared to mesalamine, nearly doubling the likelihood of achieving both clinical and histological remission 1, 2
• The medication is well-tolerated with a low incidence of serious adverse events and convenient once-daily dosing 1

Alternative Induction Options (When Budesonide is Not Feasible)

When budesonide cannot be used due to cost, contraindications, or patient preference, consider the following alternatives in order:

• Mesalamine 3 g daily as second-line therapy (conditional recommendation, moderate-quality evidence) 1
• Bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks) as third-line option (conditional recommendation, low-quality evidence) 1, 2
• Prednisolone or prednisone as fourth-line alternative, particularly when cost is prohibitive (conditional recommendation, very low-quality evidence) 1, 2

Therapies to Avoid

• Do not use combination cholestyramine plus mesalamine, as it provides no benefit over mesalamine alone and cholestyramine interferes with other medications, particularly problematic in elderly patients with polypharmacy 1
• Do not use Boswellia serrata, which showed no statistically significant benefit and has concerns regarding product standardization 1, 2
• Do not use probiotics for induction, as evidence shows uncertain benefit with low-quality data 1, 2

Maintenance Therapy

Maintenance therapy is indicated only for patients who experience clinical relapse after discontinuing induction treatment. 2

• Approximately one-third of patients will not require any maintenance therapy 2
• For patients with recurrent symptoms, budesonide 6 mg daily is strongly recommended, reducing relapse risk by 66% (RR 0.34; 95% CI 0.19–0.6) over six months 1, 2
• An alternative schedule of 3 mg daily alternating with 6 mg daily for 12 months shows comparable efficacy 2
• Taper to the lowest effective dose and consider discontinuation after 6–12 months if disease remains quiescent 2

Long-Term Considerations

• Monitor bone health during prolonged budesonide use, as it may increase osteoporosis risk despite low systemic bioavailability 2
• Implement osteoporosis prevention and screening protocols for patients requiring long-term maintenance 2
• For corticosteroid-refractory disease, consider immunosuppressants (e.g., azathioprine) or anti-TNF agents in consultation with gastroenterology specialists 2, 3

Infectious Colitis

Diagnostic Approach

• Utilize multiplex PCR followed by guided culture on PCR-positive pathogens to confirm active infection while obtaining isolates for antibiotic susceptibility testing 4
• Standard culture methods remain important for subtyping and whole genome sequencing 4
• Look for specific clinical features: bloody diarrhea suggests invasive bacterial pathogens; leukemoid reaction may indicate Shigella; elevated white blood cell count with neutrophilia suggests bacterial sepsis 5
• Monitor platelet count trends in suspected STEC infections, as decreasing platelets during days 1–14 indicate higher HUS risk 5

Treatment Principles

• Most forms of infectious colitis are treatable with antimicrobials once the pathogen is identified 4
• Reassess fluid and electrolyte balance, nutritional status, and antimicrobial dosing in patients with persistent symptoms 5
• Follow-up testing is generally not recommended for case management after symptom resolution, except when required by local health authorities for return to childcare, employment, or group activities (particularly for Salmonella Typhi, Paratyphi, STEC, and Shigella) 5

When to Reconsider Diagnosis

• For symptoms lasting ≥14 days with unidentified sources, consider noninfectious conditions including inflammatory bowel disease and post-infectious IBS 5
• Clinical and laboratory reevaluation is indicated for patients not responding to initial therapy, including consideration of lactose intolerance 5

Ischemic Colitis

Recognition and Diagnosis

• Ischemic colitis results from colonic hypoperfusion and is often underdiagnosed, particularly in ICU patients where sedation and ventilation mask characteristic features 6
• Colonoscopy is considered the gold standard for diagnosis 6
• Bedside colonoscopy and diagnostic laparoscopy are reliable options for critically ill patients in ICU settings 6

Management Approach

• Clinical presentation and treatment vary widely depending on the degree of ischemia 6
• Management is primarily supportive with bowel rest, fluid resuscitation, and correction of underlying hypoperfusion
• Surgical intervention may be necessary for transmural infarction or perforation
• Be vigilant for complications in ICU patients, as nonspecific symptoms can mimic other abdominal pathologies 6

Key Clinical Pitfalls

• Do not assume all chronic watery diarrhea is infectious—microscopic colitis requires histological diagnosis from colonic biopsies taken during colonoscopy with normal or near-normal endoscopic appearance 7, 3
• Do not overlook incomplete forms of microscopic colitis in routine clinical settings, as they risk being missed 7
• In checkpoint inhibitor-induced microscopic colitis, consider a more aggressive therapeutic approach with biologics introduced early 7
• Recognize that microscopic colitis is not associated with colorectal cancer risk, but recent data shows increased risk of lymphoma and lung cancer 7
• For immune-mediated colitis from checkpoint inhibitors, infliximab demonstrates shorter time to clinical response compared to vedolizumab, though both have comparable overall efficacy 8